CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Madrigal Pharmaceuticals, Inc. (Extended hours) - MDGL CFD

303.76
0.03%
Market Trading Hours* (UTC) Open now
Closes on Thursday at 00:00

Mon: 09:00 - 00:00

Tue - Thu: 00:00 - 01:00 09:00 - 00:00

Fri: 00:00 - 01:00 09:00 - 22:00

  • Summary
  • Historical Data
Trading сonditions
Spread 2.32
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.02)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 304.45
Open 309.77
1-Year Change 30.68%
Day's Range 303.98 - 309.77
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 309.77 2.73 0.89% 307.04 314.65 303.95
Dec 16, 2024 310.02 8.07 2.67% 301.95 311.85 297.96
Dec 13, 2024 303.10 3.06 1.02% 300.04 306.26 294.96
Dec 12, 2024 301.75 -5.18 -1.69% 306.93 310.39 299.95
Dec 11, 2024 306.42 -6.53 -2.09% 312.95 314.18 304.60
Dec 10, 2024 312.72 -2.15 -0.68% 314.87 322.06 311.10
Dec 9, 2024 317.70 -3.11 -0.97% 320.81 320.95 308.38
Dec 6, 2024 320.39 10.44 3.37% 309.95 320.84 309.93
Dec 5, 2024 313.00 -5.90 -1.85% 318.90 319.25 308.37
Dec 4, 2024 318.43 3.67 1.17% 314.76 327.95 314.76
Dec 3, 2024 321.34 3.38 1.06% 317.96 322.03 313.98
Dec 2, 2024 317.92 -7.03 -2.16% 324.95 328.73 317.31
Nov 29, 2024 327.87 -1.97 -0.60% 329.84 330.03 323.01
Nov 27, 2024 331.17 0.14 0.04% 331.03 334.62 327.05
Nov 26, 2024 336.32 -7.23 -2.10% 343.55 345.42 329.61
Nov 25, 2024 344.93 -0.14 -0.04% 345.07 350.40 340.23
Nov 22, 2024 347.28 24.10 7.46% 323.18 350.11 323.18
Nov 21, 2024 329.19 11.54 3.63% 317.65 329.36 314.64
Nov 20, 2024 317.02 4.07 1.30% 312.95 323.47 308.78
Nov 19, 2024 314.04 10.08 3.32% 303.96 320.39 301.95

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Madrigal Pharmaceuticals, Inc. Company profile

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Madrigal Pharmaceuticals Inc revenues was not reported. Net loss increased 20% to $241.8M. Higher net loss reflects R & D increase of 11% to $194.5M (expense), G & A increase from $10M to $21.1M (expense), Stock-based Compensation in SGA increase of 36% to $16.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$13.09 to -$14.63.

Equity composition

Common Stock $.0001 Par, 10/10, 100M auth., 42,166,779 issd. Insiders control approx. 37.8%. IPO: 2/06/07, 5M shares @ $10 per share by Bear, Stearns & Co. Inc.

Industry: Bio Therapeutic Drugs

200 Barr Harbor Dr Ste 400
WEST CONSHOHOCKEN
PENNSYLVANIA 19428-2978
US

People also watch

ETH/USD

3,849.21 Price
-1.780% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.50 Price
-2.820% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01249

Gold

2,639.72 Price
-0.270% 1D Chg, %
Long position overnight fee -0.0055%
Short position overnight fee -0.0027%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,921.20 Price
-0.070% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading